Work

MEK inhibitors in non-V600 BRAF mutations and fusions

Year: 2020

Type: article

Abstract: // Douglas B. Johnson 1 , Caroline A. Nebhan 1 and Marcus S. Noel 2 1 Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN, USA 2 Department of Medicine, Georgetown University Medical Center, Washington, DC, USA Correspondence to: Douglas B. Johnson, email: [email protected] Keywords: trametinib; MEK; BRAF; atypical; fusion Received: October 09, 2020 Accepted: October 13, 2020 Published: November 03, 2020 Copyright: © 2020 Johnson et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Mutations in BRAF at the 600th codon have proven sensitive to combination BRAF and MEK inhibition. Mutations outside this codon, however, are approximately as common but do not have approved targeted therapy approaches. Herein, we discuss targeting these non-V600 mutation and fusions in BRAF with MEK inhibitors.

Source: Oncotarget

DOI: 10.18632/oncotarget.27788

Authors: Douglas B. Johnson, Caroline A. Nebhan, Marcus S. Noel

Institutions: Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Georgetown University Medical Center

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: diamond

Funder: National Cancer Institute